Welcome to our dedicated page for Abbvie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading about AbbVie’s sprawling drug pipeline, patent cliffs, and FDA milestones inside a 300-page 10-K can be daunting. Add tables that track Humira biosimilar erosion and footnotes on Allergan-related intangibles, and even seasoned analysts look for help. That’s why this page exists—AbbVie SEC filings explained simply, without losing the critical details investors need.
Stock Titan’s AI breaks down every document the moment it hits EDGAR. Whether you need an AbbVie annual report 10-K simplified for pipeline probability math, an AbbVie quarterly earnings report 10-Q filing summarizing segment sales, or an AbbVie 8-K material events explained after a surprise FDA letter, our platform highlights the numbers and narrative that move ABBV shares. Real-time alerts surface AbbVie Form 4 insider transactions real-time, turning raw data into context within minutes. The same engine powers deeper AbbVie earnings report filing analysis that links management commentary to model-ready metrics.
Investors often ask how to spot patent-expiration risk or track Botox Aesthetics revenue in SEC disclosures. Here’s where to look:
- Form 4—monitor AbbVie insider trading Form 4 transactions and AbbVie executive stock transactions Form 4 before key drug launches.
- 10-Q / 10-K—compare R&D spend vs. pipeline progress with AI-generated heat maps.
- DEF 14A—the AbbVie proxy statement executive compensation reveals incentives tied to new-drug approvals.
From “understanding AbbVie SEC documents with AI” to setting custom alerts for upcoming trials, Stock Titan equips you to act on the data, not just read it.
Azita Saleki-Gerhardt, Executive Vice President and Chief Operations Officer of AbbVie Inc. (ABBV), reported transactions on 08/12/2025 showing she exercised employee stock options and simultaneously sold the resulting shares. She acquired 42,370 shares through exercise at a reported exercise price of $54.86 per share and sold 42,370 shares the same day at a weighted-average sale price of $198.42 per share. Following these transactions, her reported direct beneficial ownership decreased from 219,662 shares to 177,292 shares. The Form 4 notes 2,647 shares are held in an AbbVie savings program and 3,873 shares are held by her spouse (for which she disclaims beneficial ownership). The transactions were reported by an attorney-in-fact and the filing includes an explanatory footnote that the sale prices reported represent a range of prices between $198.34 and $198.58.
AbbVie filed a Form 144 reporting a proposed sale of 42,370 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $8,407,068.11. The filing lists the approximate date of sale as 08/12/2025 and shows the shares were acquired by a stock option exercise on 08/12/2025 with payment in cash.
The notice states there were no securities sold in the past three months by the person for whose account the shares are to be sold. The filing includes the total number of shares outstanding as 1,766,558,253, and identifies the executing broker and the class of security as common stock. No additional transaction context or identities are provided in the document.
AbbVie (ABBV) filed a Form 144 reporting proposed sales of common stock through Northern Trust Securities on the NYSE. The notice lists three proposed transactions: 61,500 shares (aggregate market value $12,043,268.25, approx. sale date 08/01/2025), 35,120 shares ($6,828,296.22, 08/04/2025) and 91,600 shares ($19,208,000, 08/04/2025). The filing shows a reported number of outstanding shares of 1,766,558,253.
The document discloses the acquisition history for the securities to be sold, showing they were received as restricted stock in grants dated between 02/28/2017 and 02/26/2021 with specific grant amounts listed. The filer indicates no securities sold in the past three months and includes the standard Rule 144 attestation about lack of undisclosed material adverse information.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
